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Protocol
AbstrACt
Introduction Traditional and transcatheter surgical 
treatments of severe aortic valve stenosis (SAVS) 
are increasing in parallel with the improved life 
expectancy. Recent randomised controlled trials 
(RCTs) reported comparable or non-inferior mortality 
with transcatheter treatments compared with 
traditional surgery. However, RCTs have the limitation 
of being a mirror of the predefined inclusion/exclusion 
criteria, without reflecting the ‘real clinical world’. 
Technological improvements have recently allowed 
the development of minimally invasive surgical 
accesses and the use of sutureless valves, but their 
impact on the clinical scenario is difficult to assess 
because of the monocentric design of published 
studies and limited sample size. A prospective 
multicentre registry including all patients referred for 
a surgical treatment of SAVS (traditional, through full 
sternotomy; minimally invasive; or transcatheter; with 
both ‘sutured’ and ‘sutureless’ valves) will provide 
a ‘real-world’ picture of available results of current 
surgical options and will help to clarify the ‘grey 
zones’ of current guidelines.
Methods and analysis European Aortic Valve Registry 
is a prospective observational open registry designed 
to collect all data from patients admitted for SAVS, 
with or without coronary artery disease, in 16 cardiac 
surgery centres located in six countries (France, 
Germany, Italy, Spain, Switzerland and UK). Patients 
will be enrolled over a 2-year period and followed up 
for a minimum of 5 years to a maximum of 10 years 
after enrolment. Outcome definitions are concordant 
with Valve Academic Research Consortium-2 criteria 
and established guidelines. Primary outcome is 
5-year all-cause mortality. Secondary outcomes 
aim at establishing ‘early’ 30-day all-cause and 
cardiovascular mortality, as well as major morbidity, 
and ‘late’ cardiovascular mortality, major morbidity, 
structural and non-structural valve complications, 
quality of life and echocardiographic results.
Ethics and dissemination The study protocol is approved 
by local ethics committees. Any formal presentation or 
publication of data will be considered as a joint publication 
by the participating physician(s) and will follow the 
recommendations of the International Committee of 
Medical Journal Editors for authorship.
trial registration number NCT03143361; Pre-results.
strengths and limitations of this study
 ► The protocol addresses the important question of 
which surgical treatment offers the most benefits 
in the management of patients with severe aortic 
valve stenosis, with or without concomitant coronary 
artery disease. The expected large sample size will 
guide subanalyses aimed at identify specific patient 
characteristics and different risk profiles, which are 
better served with alternative surgical techniques.
 ► The minimum 5-year and maximum 10-year follow-
up will provide answers about the mid-to-long term 
safety and efficacy of recent surgical innovations (ie, 
sutureless valves, minimally invasive approaches, 
surgical transcatheter aortic valve replacement), 
whose follow-up data are still lacking in current 
literature.
 ► The present multicentre registry has clearly 
established aim, inclusion and exclusion criteria, 
short-term and follow-up primary and secondary 
endpoints, as well as state-of-the-art methods for 
data collection and endpoints definition.
 ► Limitations include variations in postoperative and 
follow-up management, which are based on local 
Institutional policies, and lack of blinding between 
the central statistical core  lab performing the 
analyses and the employed surgical techniques.
 ► The absence of any external sponsor certainly limits 
research resource allocation but also guarantees the 
certainty for the absence of any bias or conflict of 
interest related to the investigated topics.
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IntroduCtIon 
The prevalence of severe aortic valve stenosis (SAVS) 
correlates with age, and its treatment is expected to 
increase parallel to the improved life expectancy reported 
in western countries.1 2 Traditional surgical aortic valve 
replacement (SAVR) has been the gold standard of treat-
ment for decades, with well-documented benefits in terms 
of symptom improvement and survival.3 4 Recent tech-
nological advances allowed interventional and surgical 
transcatheter aortic valve replacements (TAVR), which 
proved to be effective alternatives to traditional SAVR, in 
both high-risk and intermediate-risk patients.5–12 There-
fore, SAVR and TAVR represent nowadays the standard 
surgical armamentarium for aortic valve replacement.
Alternative surgical approaches, based on the concept 
of TAVR,13 14 have in fact been developed. There are on the 
market two types of ‘sutureless’ valves (ie, Sorin Perceval 
and Edwards Intuity) at the moment—aimed at reducing 
some surgical drawbacks such as cross-clamp time and 
myocardial ischaemia-reperfusion injury13 15–20—and 
it is possible that new ‘sutureless’ valves will enter the 
market in the next future. Moreover, different minitho-
racotomy and ministernotomy approaches to SAVR have 
been widely adopted by the surgical community—with 
both ‘sutured’ and ‘sutureless’ valves—in order to reduce 
surgical trauma, systemic inflammatory response and 
major organ morbidity.13 15 16 Various different combina-
tions of minimally invasive accesses and the use of last-gen-
eration valves have been reported to date.14 17 18 However, 
despite early enthusiasm about preliminary results with 
these technological improvements, none of these tech-
niques has yet replaced traditional SAVR in standard 
surgical practice, mainly because reporting of results of 
these alternative techniques tends to be biased by single-
centre design, limited sample size and the strict inclu-
sion/exclusion criteria of the published studies.13 14
Another ‘hot topic’ in this debate relates to valve dura-
bility, given that the long-term durability of both TAVR 
and sutureless valves is as yet unknown. Indeed, standard 
‘sutured’ surgical valves demonstrated excellent durability, 
both in the very long term and in very young adults below 
the 65-year cut-off age,21–23 which is still the threshold for 
biological valves recommended by European Society of 
Cardiology/European Association for CardioThoracic 
Surgery guidelines.24 This issue is of particular interest, 
given that the use of TAVR has increased in younger inter-
mediate-risk patients, despite recent caveats relating to 
early degeneration of TAVR.25 26
Similarly, improved life expectancy has led to a growing 
number of patients with degenerated dysfunctioning 
aortic bioprostheses requiring surgical treatment. Again, 
surgical aortic prosthetic replacement has been tradi-
tionally considered the only treatment strategy for these 
patients, given the excellent results, recently confirmed 
by several studies.27 28 Again, transcatheter treatments 
(‘valve-in-valve’) have recently demonstrated comparable 
or sometimes superior results in redo scenarios.29 There-
fore, data on the efficacy, safety and durability of these 
technological improvements are essential for providing 
‘strong’ statements in future guidelines and for evalu-
ating the extension of these techniques to low-risk and 
young patients in the future.
Finally, it is well known that critical coronary artery 
disease (CAD) often coexists with SAVS. Although the 
standard treatment option for these patients has tradi-
tionally been SAVR plus coronary artery bypass grafting 
(CABG), the introduction of TAVR and minimally inva-
sive surgical alternatives has considerably changed the 
available options, paving the way to combined less inva-
sive SAVR+CABG and/or TAVR± Percutaneous coronary 
intervention (PCI) (either before, during or after the 
surgical procedure).30–34 Again, there is a great deal of 
confusion on the topic, and there are unanswered ques-
tions on the efficacy and safety of these options, as well 
as on what to expect from late follow-up when compared 
with the standard practice of SAVR+CABG.
Robust early and follow-up data on the safety and effi-
cacy of surgical TAVR, last-generation sutureless surgical 
valves and minimally invasive approaches compared with 
standard SAVR, with or without a contemporary (surgical 
or interventional) treatment of concurrent CAD, are still 
lacking for a real-world large population of patients at 
variable surgical risk. Such data are urgently required for 
the correct allocation of therapy in daily surgical practice. 
Furthermore, data on quality of life (QoL) and func-
tional echocardiographic results with different surgical 
alternatives might similarly help physicians in deci-
sion making in local ‘Heart Teams’. Data from a multi-
centre, real-world, open registry enrolling all patients 
with SAVS±CAD consecutively referred to several centres 
at different European latitudes should help to answer 
some of these open questions. Here, we describe the 
rationale and the study protocol of the European Aortic 
Valve Registry (E-AVR), a multicentre prospective obser-
vational open registry on aortic valve surgical practice.
MEthods And AnAlysIs
rationale of the study and aim
Improvements in surgical treatment of cardiac diseases 
can be obtained with the implementation of current 
techniques and the development of new methods, based 
on information from large clinical datasets.35 The main 
strength of a prospective clinical open registry is the 
high external validity, given that data are collected in 
the settings of standard clinical practice. Moreover, large 
sample size enables a better estimation of event rates and 
allows the investigation of hard endpoints and outcomes 
by means of a wide population of patients from different 
institutions and with extremely limited exclusion criteria.
Importantly, clinical registries may provide data on 
long-term outcomes occurring after the study period 
of a trial.35 They are more practical than randomised 
controlled trials, require fewer resources and have less 
stringent inclusion and exclusion criteria for patient 
enrolment. Finally, clinical findings from registries have 
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even more significance when patient populations derive 
from different geographic areas, with heterogeneous 
referral pathways, baseline clinical characteristics and 
perioperative treatment strategies. All these features 
substantiate the concept of ‘a real world practice’ under-
lying any ‘registry-study’.
Therefore, the rationale of this European multicentre 
observational open registry is to prospectively collect data 
on baseline characteristics, treatment options, periop-
erative management and postoperative outcome of all 
patients consecutively undergoing surgical treatment of 
SAVS (regardless of gradients, aortic valve area (AVA) or 
Indexed Aortic Valve area (AVAi))±CAD or aortic pros-
thetic dysfunction±CAD at 16 European university or 
non-university tertiary hospitals located in six European 
countries (France, Germany, Italy, Spain, Switzerland and 
UK). The complete list of E-AVR Collaborators is reported 
in the online supplementary appendix.
The primary aim of the study is a 5-year comparison 
between SAVR and surgical TAVR; we hypothesise to 
report a 10% inferior 5-year all-cause mortality event rate 
in SAVR, that is, we expect that SAVR survival will exceed 
by 10% (absolute value) that of surgical TAVR. For the 
purpose of this study, patients will be consecutively 
enrolled for a 2-year period and will be followed up for 
a minimum of 5 years after the index surgical treatment. 
Maximum follow-up length will be 10 years after surgery.
The following surgical options will be considered:
1. SAVR with mechanical valves
2. SAVR with biological valves (either sutured or suture-
less, stented or stentless)
3. surgical TAVR (either transapical, transaxillary or 
transaortic).
Similarly, the following surgical approaches will be 
considered:
1. full sternotomy
2. minithoracotomy (either left sided for TAVR or 
right sided for SAVR)
3. partial sternotomy.
Patient allocation to a specific surgical procedure will 
be based on the local Heart Team decision at each Institu-
tion, according to standard clinical practice and current 
guidelines.2
A flow chart of the enrolment criteria and of the 
surgical techniques considered in the registry is provided 
in figure 1.
Criteria for registry enrolment
The following inclusion and exclusion criteria will be 
considered.
Inclusion criteria
 ► Age >18 years old
 ► isolated SAVS with or without concomitant aortic 
valve regurgitation
 ► isolated prosthetic aortic dysfunction
 ► SAVS+CAD
 ► prosthetic aortic dysfunction+CAD
Figure 1 Flow chart of enrolment criteria and surgical techniques considered in the registry. CABG, coronary artery bypass 
grafting; CAD, coronary artery disease; SAVS, severe aortic valve stenosis; TAVR, transcatheter aortic valve replacement.
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 ► elective, urgent and emergent procedures
 ► endocarditic aetiology.
Exclusion criteria
 ► Patients undergoing concomitant mitral valve surgery, 
or tricuspid valve surgery, or aortic surgery (ie, 
composite aortic valve and ascending aorta replace-
ment with o without circulatory arrest), or atrial fibril-
lation surgery, or any other associated cardiac surgical 
procedure (with the exception of CABG)
 ► concomitant aortic root procedure (ie, Bentall opera-
tion, David operation, homografts and autografts)
 ► SAVR with techniques of aortic annular enlargement
 ► porcelain aorta
 ► pure aortic valve regurgitation
 ► percutaneous TAVR (regardless of technique, ie, 
either by a completely percutaneous approach or by 
surgical cut-down)
 ► patient refusal.
Patients will be recruited in a consecutive series from 
each institution, and their data will be collected in a dedi-
cated online datasheet. The recruitment period will be 
24 months, from 1 November 2017 to 30 October 2019. 
Every patient will be followed up at 30 days, 6 months, 
1 year and yearly thereafter, up to a minimum of 5 years 
after the index surgical procedure (figure 2). Afterwards, 
yearly follow-up will be closed at the completion of the 
10th year from surgery for each patient.
On the basis of historical cohort data of local institu-
tions, we expect to enrol a minimum of 4000 patients at 
the end of the first year and a minimum of 8000 patients 
at the end of the second year of enrolment.
Informed consent
Written informed consent will be obtained from the 
patient or patient’s authorised representative prior to 
enrolment in the registry. In case of emergent surgery, 
informed consent will be collected from the patient’s 
family (or legal representative) before surgery, as well as 
from the patient after surgery (if unable to give it before 
intervention). This consent will be waived in case of death 
or severe neurological damage precluding adequate 
postoperative patient informed consent. The study will 
be conducted in accordance with the provisions of the 
Declaration of Helsinki. The study is registered in  Clini-
caltrials. gov. (no. NCT03143361).
data management and monitoring
Data will be collected into a dedicated datasheet with 
predefined variables. Each patient enrolled in the 
registry will be anonymised by the generation of a code 
consisting of the initials of the enrolling country (two 
letters), enrolling centre (two letters) and then consecu-
tive number (considered at thousands) (eg, Mr XY, third 
patient enrolled in London=UKLO0003). It is the respon-
sibility of the E-AVR Steering Committee local member 
to generate the sequence to maintain anonymised the 
entire set of data. It is also the responsibility of the E-AVR 
Steering Committee local member to protect confidenti-
ality about patient identity before, during and after the 
trial. Accordingly, the external Central Statistical Core 
Figure 2 Flow chart of time-points for data collection.
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Lab (as well as all the other E-AVR investigators) will be 
blinded towards patient identity.
All data will be retained in a secure location at each 
study site during the conduct of the study and for the 
5 years after the end of the study, when all patient iden-
tifiable paper records will be destroyed by confidential 
means.
Baseline characteristics, operative details and outcome 
data pertaining hospitalisation will be prospectively 
collected from hospital registries. Variables and events 
occurring after the index hospital discharge will be 
collected from outpatient clinics at the individual Insti-
tutions, and linking with regional Social Security Death 
and Events Master files where available. In case of absent/
missing data, variables and events will be collected by 
direct phone contact with general practitioners and only 
if persistently missed by phone contact with patients and 
families.
Events and outcome variables will be adjudicated 
centrally by a Central Core Lab (Unit for Clinical 
Research and Biostatistics, Verona University Hospital, 
Verona, Italy). In the event of controversy on outcome 
adjudication, this will be discussed and adjudicated after 
a final consult between the Central Core Lab and the 
E-AVR Steering Committee.
Storage, analysis and auditing of data will be also 
accomplished by the independent Central Core Lab. 
Auditing of the dataset will be performed every 6 months 
by checking the data of a minimum of 40% of the 
patients. Data without any patient identification code 
will be submitted to the principal investigator (PI) and 
E-AVR Steering Committee for further data checking and 
merging. Incomplete or contradictory data with patient 
identification code will be sent from Central Core Lab 
to the E-AVR Steering Committee local member for 
further data checking, review, correction and merging. 
The entire set of statistical analyses will be available to all 
E-AVR researchers for the interpretation of data.
statistical methods
The Central Core Lab (Unit for Clinical Research and 
Biostatistics, Verona University Hospital, Verona, Italy) 
will perform all the statistical analyses derived from this 
registry.
It is intended to enrol 8000 patient, of which 60%–70% 
will be SAVR and the remainder TAVR (historical data 
based on institutional practices). Considering the esti-
mated event rate of 25% in the TAVR patients at 5 years,36 
a 2-year accrual time, an anticipated loss-to-follow-up rate 
of 1.5% (historical data) and the target power of 80% at 
a 0.05 one-sided log-rank test significance level to detect 
the hypothesised 10% inferior (absolute improvement) 
5-year all-cause mortality rate in favour of SAVR, the 
calculations showed the overall sample size of the registry 
to meet the targeted power for all expected scenarios of 
estimated proportions of SAVR and TAVR patients.
Similar calculation shows that, considering the esti-
mated 30-day all-cause mortality event rate of 5.0% after 
SAVR and of 5.5% after TAVR (0.5% absolute difference) 
in intermediate-risk patients,37 the overall sample size of 
the registry also meets the targeted 80% power to detect 
a difference as small as 0.5% in 30-day all-cause mortality 
event rate in favour of SAVR. Other secondary endpoints 
will serve as exploratory analyses, possibly useful for 
sample size estimation of future clinical trials.
Statistical calculations were accomplished with PASS 
14.0 Power Analysis and Sample Size Software (2015) 
statistical package (NCSS, LLC; Kaysville, Utah, USA; 
ncss. com/ software/ pass).
Continuous variables will be reported as mean and SD 
or median and IQR, as appropriate. Dichotomous and 
nominal variables will be reported as counts and percent-
ages. Univariate analysis will be performed using the 
Mann-Whitney U test and Student’s t-test for continuous 
variables (pending the not-normal or normal distribu-
tion, respectively), the Kruskal-Wallis test (independent 
multilevel ordinal variables), Wilcoxon test (for paired 
variables), Fisher’s exact test and χ2 test (for dichoto-
mous/nominal variables) and Kaplan-Meier test (for 
time-dependent dichotomous variables). Log-rank test 
will be used to compare the 5-year all-cause mortality rate 
between SAVR and surgical TAVR. Multivariable anal-
yses will be performed using logistic regression method 
(for categorical dependent variable), classification tree 
analysis (for target variables with a discrete set of value), 
linear regression (for continuous dependent variable) 
and ordinal regression methods (for ordinal dependent 
variable). Cox proportional hazards method will test the 
effects of covariates on time-dependent dichotomous vari-
ables; the model’s proportional hazard assumption will 
be checked using the Schoenfeld residuals test. Signifi-
cant differences between study groups will be adjusted 
by using propensity score as covariate or by one-to-one 
propensity score matching. Matching will be performed 
using a calliper width of 0.2 of the SD of logit of the 
propensity score. Multiple propensity score adjusted anal-
ysis will be performed in case of multiple study groups. A 
Bayesian hierarchical approach will be used in the case of 
significant variability between centres.
Missing values will be replaced and estimated using 
multiple imputations. Furthermore, sensitivity analysis 
will be executed using complete-case analysis. Interim 
analyses are planned at different time-points (see Ethics 
and dissemination). Critical P values of accomplished 
interim analyses will be corrected according to the Armit-
age-McPherson adjustment.38
Early and late endpoints
Outcome endpoints will be defined according to 
current guidelines, that is, Valve Academic Research 
Consortium-2 (VARC-2) definitions39 and guidelines for 
reporting mortality and morbidity after cardiac valve 
interventions.40
In more detail, the following outcome variables will be 
collected:
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Primary outcome of the E-AVR registry
Five-year all-cause mortality.
Secondary outcomes of the E-AVR registry
These will be dichotomised into ‘early’ at 30 days 
(ie, during hospitalisation, at home if discharged or 
during ‘rehab-hospitalisation’ at any time-point if 
never discharged home) and ‘late’ (after the patient is 
discharged home):
1. Early secondary outcomes: all-cause mortality, cardio-
vascular mortality, stroke, acute myocardial infarction 
(AMI),41 postoperative need for prolonged use of ino-
tropes (>72 hours), postoperative need for intra-aortic 
balloon pump (IABP) or extracorporeal mechanical 
oxygenation (ECMO), surgical site infection, blood 
losses and use of blood products (during hospitalisa-
tion for the index surgical procedure), nadir haema-
tocrit, nadir haemoglobin, resternotomy for bleeding, 
atrial fibrillation (first event and number of events), 
cardiac conduction disturbances, need for new per-
manent pacemaker implantation, acute kidney injury 
(following acute kidney injury (AKIN) classification), 
pericardial effusion requiring treatment, length of 
stay in the intensive care unit, length of inhospital stay 
(for the index procedure), device success, early safety, 
clinical efficacy, time-related valve safety, echocardio-
graphic data of prosthesis performance and early re-
peat surgery for failure of the index procedure (any 
‘redo’ before discharge home or to rehabilitation 
clinic).
2. Late secondary outcomes (collected starting from dis-
charge to the end of the 10th year after the index pro-
cedure): cardiovascular mortality, all-cause mortality 
(from 1 year to 4 years after surgery, then from 6 years 
to 10 years), stroke, AMI, reintervention on the aortic 
prosthesis, repeat revascularisation (either with per-
cutaneous coronary intervention or CABG), prosthet-
ic thrombosis, embolism, bleeding events, structural 
valve deterioration, paravalvular leakage, prosthetic 
endocarditis, need for permanent pacemaker, need 
for implantable cardioverter-defibrillator, Major 
Cardiovascular and Cerebrovascular Events (MACCE) 
(defined as a composite endpoint including any of 
the following adverse events: death from cardiovas-
cular cause, stroke, myocardial infarction and repeat-
ed revascularisation), time-related valve safety, QoL 
defined according to Short Form-8 (SF-8) question-
naire; QoL will be assessed during follow-up visits at 
outpatient clinics or, if other methods are not possi-
ble, by telephone interview); echocardiographic data 
of prosthesis performance.
Echocardiographic data of prosthesis performance 
are defined according to the VARC-2 definitions.38 All 
echocardiographic data will be collected from third level 
nationally and/or internationally certified Institutional 
Echo Laboratories: 5% of these echocardiographic exams 
will be reviewed centrally (Unit for Clinical Research and 
Biostatistics, Verona University Hospital, Verona, Italy) 
by third-level certified echocardiographers. Collection of 
data is under the responsibility of the steering committee 
local member at each participating centre. Data will be 
audited from the Central Core Lab on a regular basis, as 
reported previously.
Outcomes and their definition criteria are described in 
detail in the following section of this article.
data collection
Participating centre
Each participating centre will be anonymised by identifi-
cation with a capital letter. The correspondence between 
centres and capital letters will only be known by the PI of 
the study. The Central Core Lab analysing the data will be 
blinded towards the surgical teams.
Units of measurement
Laboratory data will be collected according to fixed units 
of measurement in order to avoid any problem stemming 
from differences in units used by the various participating 
centres, during data merging and analysis. The fixed 
units of measurement are reported in the dedicated case 
record form (CRF) datasheet.
Laboratory parameters
Baseline levels of haemoglobin, haematocrit, platelets, 
blood glucose, Glycated Hemoglobin (HbA1c), C reac-
tive protein, International Normalized Ratio (TT-INR) 
and albumin will be collected.
Hypertension
Arterial blood pressure >140/90 mm Hg or antihyperten-
sive treatment.
Diabetes
Diabetes mellitus requiring diet, oral or insulin treatment.
Preoperative creatinine levels
This parameter is obtained on the day before surgery and 
is expressed in µmol/L.
Chronic kidney disease
The severity of renal failure will be classified as shown in 
table 1. It is stratified by the estimated glomerular filtra-
tion rate (eGFR) calculated using the Modification of 
Diet in Renal Disease Study Group modified formula.42 
eGFR for calculation of the EuroSCORE II43 will be 
Table 1 Stages of renal failure
Stages eGFR level (mL/min/1.73 m2)
1 90 or above
2 89 to 60
3a 59 to 44
3b 44 to 30
4 29 to 15
5 Less than 15 or on dialysis
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estimated using the Cockcroft-Gault formula44 according 
to the criteria of this risk scoring method.
Dialysis
Peritoneal or haemodialysis before surgery.
Chronic obstructive pulmonary disease
Any long-term use of bronchodilators or steroids for lung 
disease.
Oxygen therapy
Long-term oxygen therapy for respiratory failure.
Liver disease
Different degrees of liver failure stratified according to 
the Child-Pugh classification.45
Active neoplasia
Any active malignancy.
Preoperative stroke
Any preoperative focal or global neurological syndrome 
caused by ischaemia or haemorrhage not resolving within 
24 hours.
Neurological dysfunction
Disabling outcomes in ambulation and/or normal motor 
functions, according to EuroSCORE II definition.43
Extracardiac arteriopathy
One or more of the following: claudication, carotid occlu-
sion or >50% stenosis, amputation for arterial disease, 
previous or planned intervention on the abdominal 
aorta, limb arteries or carotids.
Preoperative ECG
Sinus rhythm or atrial fibrillation, or first degree atrio-ven-
tricular (AV) block, or right bundle block, or left bundle 
block or pacemaker rhythm.
Preoperative myocardial infarction
Any preoperative myocardial infarction.
Previous vascular surgery
History of surgical or endovascular procedure of the 
thoracic or abdominal aorta and/or the iliac-femoral 
arteries.
Previous cardiac surgery
One or more previous cardiac operations requiring 
opening of the pericardium.
Type of previous cardiac surgery
Description of previous cardiac operation.
Previous aortic valve replacement
Description of prosthesis and date of operation.
Previous percutaneous coronary intervention
Any previous percutaneous coronary intervention.
Aetiology of aortic valve disease
Native valve disease (degenerative, rheumatic and endo-
carditic) or prosthetic valve disease.
Endocarditis
Any diagnosis of valve endocarditis made by the Heart 
Team and/or antibiotic treatment for endocarditis at the 
time of surgery. Subclassification into acute, subacute and 
healed endocarditis based on current guidelines will be 
added.46
Endocarditis aetiology
Microbe isolated for the diagnosis of endocarditis.
New York Health Association (NYHA) functional classes
Defined according to the criteria listed in table 2.47
Aortic valve stenosis
Severity of aortic valve stenosis before surgery will be 
graded as moderate or severe according to 2014 Amer-
ican Heart Association (AHA)/American College of 
Cardiology (ACC) guidelines for the management of 
patients with valvular heart disease.48
Aortic valve regurgitation
Severity of aortic valve regurgitation before surgery will be 
graded in classes from 0 to 3, and the grade of severity will 
be evaluated according to 2014 AHA/ACC guidelines for 
the management of patients with valvular heart disease.48
Associated critical CAD
Presence of stenosis of at least 70% in any major epicar-
dial coronary artery. Number of main vessels involved 
will be recorded. Patients with stenosis of the left main 
Table 2 New York Heart Association functional classes
Class Definition
I Cardiac disease, but no symptoms and no limitation in ordinary physical activity, for example, no shortness of breath 
when walking, climbing stairs and so on.
II Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.
III Marked limitation in activity due to symptoms, even during less-than-ordinary activity, for example, walking short 
distances (20–100 m). Comfortable only at rest.
IV Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.
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coronary artery will be considered as having at least 
two-vessel disease.
Associated left main CAD
Any LMSD >50%.
Mitral valve regurgitation
Severity of concurrent mitral valve regurgitation—
though not requiring surgery—will be graded in classes 
according to 2014 AHA/ACC guidelines for the manage-
ment of patients with valvular heart disease.48
Left ventricular (LV) function: last measured LV ejec-
tion fraction before surgery (in any case before induction 
of anaesthesia).
Pulmonary hypertension
Absent: <31 mm Hg; moderate: 31–55 mm Hg; severe: 
>55 mm Hg, according to EuroSCORE II definition.43 
Systolic pulmonary pressure will be estimated at echocar-
diography, at least before induction of anaesthesia.
Preoperative echocardiography data
Aortic valve area, peak transvalvular gradient, mean trans-
valvular gradient, aortic annulus diameter, maximum jet 
velocity (transthoracic echocardiography (TTE) will be 
recorded.
Preoperative multislice CT scan data
Annulus circumference, valvular area and calcium score 
(collected for all surgical TAVR, and only if available for 
other surgical techniques).
Diseased ascending aorta
Any sign of diffuse atherosclerosis in the ascending aorta 
at palpation or epiaortic ultrasound (porcelain aorta is 
not considered).
Montgomery classification
If available, echocardiographic Montgomery classifica-
tion of aortic atheromas will be provided.
Preoperative antithrombotic or antibiotic drug treatment
Data on all antithrombotic drugs administered before 
surgery will be collected. The date of pause of drug treat-
ment is the last day the patient received the drug. Data on 
any oral or intravenous antibiotics administered preop-
eratively without prophylaxis purpose, that is, for any 
preoperative infectious condition, will be collected.
Elective surgery
Elective procedure scheduled for stable aortic valve 
disease.
Urgent surgery
Procedure indicated by medical factors that require 
the patient to stay in hospital to have operation before 
discharge.
Emergency surgery
Procedure performed before the beginning of the 
working day after the decision to operate.
Frailty
Preoperative patient’s frailty is graded according to Geri-
atric Status Scale, as proposed by Rockwood et al.49
Critical preoperative status
Ventricular tachycardia or ventricular fibrillation or 
aborted sudden death, preoperative cardiac massage, 
preoperative ventilation before anaesthetic room, preop-
erative inotropes or IABP and preoperative acute renal 
failure (anuria or oliguria <10 mL/hour) according to 
EuroSCORE II definition.43
EuroSCORE II
This risk score is calculated using the on-line calculator 
available at http://www. euroscore. org/ calc. html and 
reported as a percentage. The risk factors included in the 
EuroSCORE II and collected in the E-AVR registry are 
defined according to the EuroSCORE II criteria.42
STS score
This risk score is calculated using the online calculator 
available at http:// riskcalc. sts. org/ stswebriskcalc/#/ and 
reported as a percentage. The risk factors included in the 
Society of Thoracic Surgeons (STS) score and collected 
in the E-AVR registry are defined according to the STS 
score criteria.50
Surgical chest access
Classified as (1) full sternotomy,  (2) minithoracotomy and 
(3) partial sternotomy.
Aortic valve replacement data
Classified as (1) mechanical prosthesis, (2) stented biolog-
ical prosthesis, (3) stentless biological prosthesis, (4) 
sutureless biological prosthesis, (5) transapical TAVR and 
(6) transaortic TAVR. The description of model and 
diameter of the prosthesis implanted and possible need 
for proctored procedure will also be collected.
Other intraoperative data
Type of cardioplegia and its temperature, duration of 
extracoroporeal circulation (ECC), nadir tempera-
ture of ECC and aortic cross-clamping time, need 
for re-aortic cross-clamping for any reason (paraval-
vular leak, coronary obstruction, annular rupture/
haematoma, reconstruction of CABG and so on), as 
well as details of TAVR implantation including sheath 
size, preimplantation valvuloplasty, occurrence of 
valve-in-valve emergency procedure, the number of 
valves implanted, prosthesis migration, recapturing 
and repositioning of the valve, postprocedural dila-
tion and amount of contrast medium administered 
will be collected.
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CABG details
Details of types of conduit and target vessel will be reported 
(eg, LIMA-LAD, RIMA-Dx, RA-MO and SV-DIAG). The 
following specifications for conduits will be used: LIMA: 
left internal mammary artery; RIMA: right internal 
mammary artery; RA: radial artery; GEA: gastro-epiploic 
artery; SV: saphenous vein. The following target acronyms 
will be used: DA: anterior descending; DIAG: diagonal; 
RX: right coronary (trunk); PDA: posterior descending; 
PL: posterolateral; OM: obtuse marginal. In the event of 
sequential grafting, the prefix ‘seq’ will be used before 
targets (eg, LIMA-seq DIAG-DA).
Other CABG details
Number of distal anastomoses, completeness of 
revascularisation.
30-day all-cause mortality
Defined as the sum of cardiovascular and non-cardiovas-
cular, the latter defined as any death in which the primary 
cause is clearly related to another condition not contem-
plated by the definition ‘cardiovascular’ (eg, trauma and 
cancer), as in VARC-2 definition,39 but occurring within 
30 days or during index procedure hospitalisation if the 
postoperative length of stay is longer than 30 days.
30-day cardiovascular mortality
Based on VARC-2 definition39 and occurring within 
30 days or during hospitalisation for the index proce-
dure if the postoperative length of stay is longer than 
30 days. This includes: (1) death due to proximate 
cardiac cause (eg, myocardial infarction, cardiac 
tamponade, worsening heart failure and low cardiac 
output syndrome); (2) death caused by non-coro-
nary vascular conditions (eg, pulmonary embolisms, 
stroke, aortic rupture or vascular dissection); (3) all 
procedure-related deaths (including those related to 
a complication of the procedure or a treatment for 
a complication of the procedure); (4) all valve-re-
lated deaths including valve dysfunction (structural 
or non-structural) and other valve-related adverse 
events; and (5) sudden or unwitnessed death.
Type 5 myocardial infarction
Defined according to the recent criteria defined by 
Moussa et al51 (table 3).
Atrial fibrillation
Any new paroxysmal/permanent atrial fibrillation 
episode requiring or not requiring pharmacological or 
electrical cardioversion attempts. Number of recurrences 
will be also collected.
Cardiac conduction disturbances
Defined as a new left bundle branch block, right bundle 
branch block or AV block (first, second or third degree). 
Diagnosis will be based on official medical reports from 
a consultant cardiologist. In case of progressive bradi-
arrhythmias, the evolution of the arrhythmias will be 
collected.
Need for permanent Pacemaker
Collected as a dichotomic variable. Type of permanent 
pacing set-up (eg, Atrio-Atrial Inhibited (AAI), Ventric-
ular-ventricular inhibited (VVI) and Dual chamber 
sensing/pacing (DDD)) will be collected.
Postoperative neurological damage
Classified as: (0) absent, (1) disabling stroke, (2) non-dis-
abling stroke and (3) TIA, based on definitions of VARC-2 
consensus.39
Stroke classification
(1) Ischaemic, (2) haemorrhagic and (3) unknown, 
according to VARC-2 consensus.39 The diagnosis and 
nature of stroke will be supported by CT or MRI imaging 
and confirmed by a consultant neurologist.
Table 3 Definition criteria of type V myocardial infarction
Baseline condition Definition
1. In patients with normal baseline CK-
MB or cTn (I or T)
The peak CK-MB measured within 48 hours of the procedure rises to ≥10 ×  the 
local laboratory upper limit of normal (ULN) or to ≥5 ×  ULN with new pathological 
Q-waves in ≥2 contiguous leads or new persistent LBBB, OR in the absence of CK-
MB measurements and a normal baseline cTn, a cTn (I or T) level measured within 
48 hours of the procedure rises to ≥70 ×  the local laboratory ULN, or ≥35 × ULN with 
new pathological Q-waves in ≥2 contiguous leads or new persistent LBBB.
2. In patients with elevated baseline CK-
MB (or cTn) in whom the biomarker levels 
are stable or falling
The CK-MB (or cTn) rises by an absolute increment equal to those levels 
recommended above from the most recent preprocedure level.
3. In patients with elevated CK-MB (or 
cTn) in whom the biomarker levels have 
not been shown to be stable or falling
The CK-MB (or cTn) rises by an absolute increment equal to those levels 
recommended above plus new ST-segment elevation or depression plus signs 
consistent with a clinically relevant MI, such as new onset or worsening heart failure 
or sustained hypotension.
CK-MB, Creatinine Kinase-MB; cTnI, cardiac troponin I; cTnT, cardiac troponin T; LBBB, left bundle-branch block; MI, myocardial infarction.
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Prolonged use of inotropes (>72 hours)
This refers to the use of inotropes for >72 hours after the 
index operation. The type, dose and duration of adminis-
tered inotropes will be also collected.
Cardiogenic shock
Postoperative critical haemodynamic condition requiring 
mechanical ventricular-assist devices or high-dose 
inotropes with evidence of peripheral malperfusion. 
Coexistence of a cardiac index <1.8 L/min/m2 despite 
adequate correction of all the coexisting preload, after-
load, electrolyte and gas-analyses abnormalities will be 
pursued with the aid of different haemodynamic moni-
toring methods, according to local Institutional policies 
(eg, echocardiography, Swan-Ganz catheter, PICCO, 
PRAM and Vigileo).
Intra-aortic balloon pump
Intraoperative or postoperative insertion of an IABP 
device.
Extracorporeal mechanical oxygenation
Intraoperative or postoperative insertion of an extracor-
poreal mechanical pump/oxygenation device.
Bleeding
Classified as (1) life-threatening or disabling bleeding; 
(2) major bleeding; and (3) minor bleeding, according 
to the recent definition criteria reported by the VARC-2 
document.39
Blood loss 12 hours after surgery
The amount of postoperative blood losses from medi-
astinal drainages 12 hours after surgery. Intraoperative 
blood losses are not taken into account. Nadir haemo-
globin and nadir haematocrit will be collected.
Number of transfused red blood cell (RBC) units at 
hospital discharge: total amount of RBC units intraop-
eratively and/or postoperatively transfused from the 
beginning of surgery to the day of discharge.
Number of transfused fresh frozen plasma, pooled 
human plasma (Octaplas) and/or platelets units at 
hospital discharge: this refers to the transfusion of 
these blood products from the beginning of surgery 
to the day of discharge.
Reintervention for bleeding
Any reoperation for postoperative bleeding, regardless of 
concomitant haemodynamic problems.
Reintervention for haemodynamic problems
Any reoperation for haemodynamic instability. This can 
also be associated with excessive bleeding: in this case, 
both categories (‘Reintervention for bleeding’ and ‘Rein-
tervention for haemodynamic problems’) will be marked.
Pericardial effusion requiring treatment
Any pericardial effusion requiring interventional treat-
ment (eg, pericardiocentesis, subxifoid dreinage and 
resternotomy) due to cardiac tamponade, subtamponade 
or haemodynamic instability refractory to conservative 
treatment strategies.
Acute renal failure
Severity of acute renal failure after surgery will be graded 
in AKIN stages from 1 to 3, according to VARC-2 criteria.39
Highest postoperative creatinine level
The highest level of serum creatinine detected after 
surgery during the inhospital stay. Creatinine levels will 
be reported in µmol/L.
Renal replacement therapy
The need for renal replacement therapy will be dichoto-
mised into ‘temporary’ or ‘permanent’ (the latter in the 
event of death while on renal replacement therapy, or if 
discharged on renal replacement therapy, or in case of 
life-long need). Type of renal replacement therapy (eg, 
dialysis, continuous veno-venous hemofiltration (CVVH) 
and slow continuous ultrafiltration (SCUF)) will be also 
collected as a note.
Gastrointestinal complications
Any gastrointestinal complication requiring endoscopy 
and/or surgical treatment. Endoscopic diagnostic proce-
dures without any associated interventional procedure 
(diagnostic only) will not fit this definition.
Postoperative infection
Classified as: (1) surgical site infection, (2) organ infec-
tion (respiratory, urinary and gastrointestinal infection), 
(3) systemic infection (sepsis) and (4) index valve/device 
infection. Wound complications are graded according 
to the Centre for Disease Control and Prevention defi-
nitions of surgical site infections.52 Any surgical site 
infection occurring within 3 months after surgery will be 
considered as a postoperative wound infection.
Early repeated intervention for index intervention failure
This refers to any surgical or percutaneous procedure on 
the aortic valve and/or the coronary arteries, performed 
during the same hospital stay for any prosthesis-related or 
graft-related complication. These events will be marked 
as occurring or not, and further detailed in their nature 
(‘valvular early procedure’, ‘coronary early procedure’ or 
‘coronary+valvular early procedure’). Further details will 
be collected as explanatory notes.
Length of stay in the intensive care unit
Number of hours spent in the intensive care unit from 
surgery. Readmissions to intensive care unit will be consid-
ered and included in the number estimation.
Length of inhospital stay
Number of days spent in the hospital (ICU stay will be 
added) from the day of surgery to hospital discharge to 
any other hospital ward, rehabilitation unit or home.
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Drug antithrombotic treatment at discharge
Collected dichotomic (yes/no) for each of the following 
drugs: (1) vitamin K antagonists, (2) new oral anticoag-
ulants and (3) antiplatelets. Further details on type and 
dose of each drug will be added as a note.
Type of discharge
Discharge will be categorised according to the Italian 
National Institutes of Health classification, as follows: (1) 
death; (2) discharged home; (3) discharged to rehabili-
tation clinic; (4) voluntary discharge; (5) transferred to 
other hospital for acute complications; (6) transferred to 
other hospital for other reasons; (7) transferred to rehab/
other hospital for chronic complications; (8) ordinary 
discharge+nurse assistance at home; and (9) dismissal.
NYHA at follow-up
NYHA class will be assessed at hospital discharge, at 6 
months, 1 year, yearly up to the fifth year follow-up, and 
then yearly up to follow-up closure (10 years).
Date of events
During follow-up, the date of each possible event will be 
collected as ‘dd/mm/yyyy’.
Follow-up death
Death occurring after hospital discharge. Further dichot-
omisation into cardiovascular and all-cause mortality is 
based on VARC-2 criteria.39
Follow-up stroke
Any focal or global neurological syndrome occurring after 
discharge and caused by ischaemia and/or haemorrhage 
not resolving within 24 hours. The diagnosis and nature 
of stroke will be made on the basis of findings from brain 
CT, or MRI, or based on the medical report of a consul-
tant neurologist.
Follow-up myocardial infarction
Any myocardial infarction occurring after discharge and 
requiring medical, interventional or surgical treatment 
occurring after discharge.
Follow-up reintervention on the aortic valve
Reintervention is defined as any surgical or percuta-
neous interventional treatment that replaces (or repairs) 
an aortic prosthesis implanted at the time of the index 
procedure that is dysfunctional for either structural or 
non-structural reasons.
Follow-up aortic valve-related adverse event
This includes: (1) embolism; (2) valve thrombosis; (3) 
bleeding events; (4) structural valve deterioration; (5) 
paravalvular leakage; (6) operated valve endocarditis; and 
(7) haemolysis, based on the definitions of current guide-
lines for reporting mortality and morbidity after cardiac 
valve interventions.40
Follow-up repeated revascularisation
Any CABG and/or PCI performed after discharge for 
coronary graft dysfunction and/or valve-related coronary 
complication. Any revascularisation due to the progres-
sion of an untreated subcritical (at the time of the index 
procedure) coronary target will not be considered.
Need for implantable cardioverter-defibrillator
Collected as a dichotomous variable (yes/no).
Composite outcome
According to VARC-2 definitions,39 this includes: (1) 
device success (absence of procedural mortality with 
correct positioning of a single prosthesis and with 
intended performance of the prosthesis); (2) early safety 
at 30 days (composite endpoint of all-cause mortality, all 
strokes, life-threatening bleeding, acute kidney injury 
stage 2 or 3, coronary obstruction requiring intervention, 
major vascular complication or valve-related dysfunction 
requiring repeat procedure); (3) clinical efficacy after 
30 days (composite endpoint of all-cause mortality, all 
strokes, hospitalisation for valve-related symptoms or 
worsening congestive heart failure, NYHA class III or 
IV and valve-related dysfunction); (4) time-related valve 
safety (composite endpoint of structural valve deteri-
oration requiring repeat procedure, prosthetic valve 
endocarditis, thrombosis, thromboembolic events or 
valve-related VARC bleeding).
Follow-up MACCE
Defined as a composite endpoint occurring after the 
30-day time-point (considered as hospitalisation, 30th day 
if discharged home or during ‘rehab-hospitalisation’ at 
any time-point if never discharged home) and including 
any of the following adverse events: death from cardiovas-
cular cause, stroke, myocardial infarction and follow-up 
repeated revascularisation.
Assessment of post procedural aortic prostheses performance
Data on valve and prosthetic performances will be 
recorded according to medical reports from a consultant 
echocardiographer. Data will be collected before surgery, 
before hospital discharge, at 30 days after surgery, 6 
months, 1 year after implantation, yearly thereafter up 
to the follow-up closure (10th year). Data collected at 
echocardiographic examination are based on VARC-2 
criteria39 and aimed at exploring prosthetic valve perfor-
mance and ventricular performance. A minimum set of 
echocardiographic data will be considered, as follows: 
(1) LV function (EF% based on Simpson’s method); 
(2) indexed LV end-diastolic and end-systolic volumes 
and diameters; (3) wall motion score index; (4) indexed 
left atrial volume; (5) indexed LV mass; (6) native valve 
and prosthetic valve stenotic indexes (peak velocity, 
mean gradient, Doppler velocity index, effective orifice 
area and indexed effective orifice area); and (7) native 
valve and prosthetic valve regurgitation grade (defined 
as mild, moderate or severe based on several different 
echocardiographic indexes as regurgitant volume, 
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regurgitant fraction, effective regurgitant orifice area and 
so on based on local institutional policies). Further assess-
ment of ‘intra-prosthetic’, ‘peri-prosthetic’ or ‘combined 
intra+peri-prosthetic’ regurgitation will be added.
SF-8 Health Survey questionnaire
This will be based on eight questionnaire items reported 
in box 1.53 This examination will be administered before 
surgery, at hospital discharge, at 30 days, at 6 months, at 
1 year, yearly thereafter up to the fifth year of follow-up, 
then at follow-up closure (10th year).
Ethics and dissemination
The study is approved by the local institutional review 
boards/ethical committees according to local or national 
guidelines for approval of registry studies. Patient’s 
informed consent will be always obtained.
This multicentre, prospective open registry is designed 
with the aim of investigating a number of controversial 
issues regarding current treatment options and risk 
factors for the surgical therapy of SAVS with or without 
CAD. Several studies and information are expected to 
derive from the data collected in the registry. These 
data will provide further knowledge on the mecha-
nisms leading to adverse events during or after surgery 
for SAVS and help their prevention, thus allowing a 
‘tailored’ surgical approach for the treatment of this 
disease.
Several studies are planned at the moment:
Primary study:
1.  A 5-year study comparing all-cause mortality between 
SAVR and surgical TAVR. We expect to report a 10% 
superiority of SAVR versus TAVR according to sam-
ple size calculation and literature data.7 36 Either ad-
justed and unadjusted analyses will be performed, 
although the adjusted analysis will be of clearer val-
ue, given the expected different risk profiles of SAVR 
and TAVR patients. Adjustment will be made by 
entering as covariates all demographic and anthro-
pometric data, risk scores, comorbidities and those 
baseline characteristics (key echocardiographic and 
surgical/technical factors included) having a differ-
ent distribution at univariate analyses between the 
two patient populations. This study will also report 
echocardiographic data, functional status, QoL, in-
cidence of cardiovascular mortality, reinterventions 
on the aortic valve and incidence of structural valve 
deterioration between ‘all-comers’ surgical TAVR and 
SAVR. The study is expected 6 years after the start of 
data collection, and it is aimed at being presented in 
a major European cardiology journal.
Secondary substudies
2. An observational study providing results of the dif-
ferent surgical techniques to treat SAVS—in terms of 
‘all-cause’ and ‘cardiovascular’ mortality, major mor-
bidity and VARC-2 follow-up outcome analysis—at 
the end of the fifth year follow-up of the last patient 
enrolled. We aim at present this study in a major car-
diothoracic surgical congress and publish it in a con-
gress satellite journal. This study is expected after 6 
years from the start of data collection.
3. A study comparing early and 5-year follow-up outcome 
of mechanical versus biological prostheses in young 
population (<70 years of age). Propensity-matching 
and risk-adjusted analyses will be performed. It is 
aimed at being presented in a major American jour-
nal of the cardiology field. This study is expected af-
ter 6 years from the start of data collection.
4. A study comparing early and 5-year follow-up out-
come of stented versus stentless versus sutureless 
bioprostheses versus surgical TAVR in small annuli 
(≤21 mm). Propensity-matching and risk-adjusted 
analyses will be performed. Post hoc analysis will 
help elucidate between-group differences. It is aimed 
at being presented in a major European cardiology 
journal of the cardiology field. This study is expected 
after 6 years from the start of data collection.
5. A study comparing early and 5-year follow-up outcome 
of sutured (both stented and stentless) bioprostheses 
versus sutureless bioprostheses. Propensity-matching 
and risk-adjusted analyses will be performed. It 
is aimed at being presented in a major American 
or European journal of the cardiology field. This 
box 1 short-Form-8 health survey
Date _______________ Name _______________
This survey asks for your views about your health. This information will 
help you keep track of how you feel and how well you are able to do 
your usual activities. Answer every question by selecting the answer 
as indicated. If you are unsure about how to answer a question, please 
give the best answer you can. For each of the following questions, 
please mark an [x] in the one box that best describes your answer.
 ► Overall, how would you rate your health during the past 4 weeks?
Excellent Very Good Good Fair Poor Very Poor
 ► During the past 4 weeks, how much did physical health problems 
limit your physical activities (such as walking or climbing stairs)?
Not at all Very little Somewhat Quite a lot Could not do physical 
activities
 ► During the past 4 weeks, how much difficulty did you have doing 
your daily work, both at home and away from home, because of 
your physical health?
Not at all Very little Somewhat Quite a lot Could not do daily work
 ► How much bodily pain have you had during the past 4 weeks?
None Very mild Mild Moderate Severe Very severe
 ► During the past 4 weeks, how much energy did you have?
Very much Quite a lot Some A little None
 ► During the past 4 weeks, how much did your physical health or 
emotional problems limit your usual social activities with family or 
friends?
Not at all Very little Somewhat Quite a lot Could not do social activities
 ► During the past 4 weeks, how much have you been bothered by 
emotional problems (such as feeling anxious, depressed or irritable)?
Not at all Slightly Moderately Quite a lot Extremely
 ► During the past 4 weeks, how much did personal or emotional 
problems keep you from doing your usual work, school or other 
daily activities?
Not at all Very little Somewhat Quite a lot Could not do daily activities
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study is expected after 6 years from the start of data 
collection.
6. A 5-year outcome study comparing SAVR ver-
sus surgical TAVR in intermediate-risk patients. 
Propensity-matching and risk-adjusted analyses will 
be performed. This study is aimed at being present-
ed in a major European journal of the cardiology 
field. It is expected after 6 years from the start of data 
collection.
7. A 3-year outcome study comparing different surgical 
techniques of TAVR (ie, transapical vs transaortic vs 
transaxillary approach). Propensity-matching and 
risk-adjusted analyses will be executed if baseline 
differences are identified between the three subpop-
ulations. Post hoc statistical analyses will identify out-
come differences between the three subgroups. This 
study is aimed at being presented in a European jour-
nal of the field. This study is expected after 4 years 
from the start of data collection.
8. A 5-year outcome study resembling the previous one 
for final outcome data. This study is aimed at being 
presented in a major American journal of the field. 
It is expected after 6 years from the start of data 
collection.
9. An interim study analysing 30-day outcome of the first 
4000 patients enrolled. This study is expected after 
1 year from the start of data collection. It is aimed at 
being presented in a major European cardiothoracic 
meeting and satellite journal.
10. A study analysing 30-day outcome and 1-year fol-
low-up outcome of the first 4000 SAVR patients en-
rolled. Subgroup analyses will be aimed at compare 
different surgical accesses (ie, sternotomy vs minister-
notomy vs minithoracotomy). Propensity-matching, 
risk-adjusted and post hoc analyses will be done ap-
propriately to nullify potential bias in the interpreta-
tion of the results and to compare the results of each 
surgical subgroup. This study is expected after 2 years 
from the start of data collection. It is aimed at being 
presented in a major European cardiothoracic con-
gress and satellite journal.
11. A study analysing the 5-year outcome after 
SAVR+CABG versus TAVR±PCI (regardless of the 
surgical access for SAVR and TAVR) in patients ad-
mitted with contemporary critical aortic stenosis and 
coronary disease. Propensity-score and risk-adjusted 
analyses will be done as appropriate for a correct in-
terpretation of data. Particular attention will be fo-
cused on the role of ‘incomplete revascularisation’ 
and of different techniques of ‘staged TAVR and PCI’ 
in the transcatheter group. This study is expected af-
ter 6 years from the start of data collection. It is aimed 
at being presented in a major European cardiotho-
racic congress and satellite journal.
12. A 10-year study comparing all-cause and cardiovascu-
lar mortality, echocardiographic data, functional sta-
tus, QoL, incidence of reinterventions on the aortic 
valve and incidence of structural valve deterioration 
between SAVR and surgical TAVR. This study is ex-
pected after 11 years from the start of data collec-
tion, and it is aimed at being presented in a major 
European cardiology journal.
13. A 10-year study comparing all-cause and cardiovascu-
lar mortality, echocardiographic data, functional sta-
tus, QoL, incidence of reinterventions on the aortic 
valve and incidence of structural valve deterioration 
between SAVR with ‘sutured’ valves and SAVR with 
‘sutureless’ valves. This study is expected after 11 
years from the start of data collection, and it is aimed 
at being presented in a major cardiology journal.
For all the above-mentioned studies considering 
propensity score method, demographic data, gender, 
EuroSCORE-2, STS score, NYHA functional class, frailty 
scale, LV function, comorbidities and all those baseline 
characteristics (anthropometric data, key laboratory 
tests, echocardiographic parameters and surgical factors 
included) having a different distribution at univariate 
analyses between the two patient populations and/or 
potentially acting as bias will be included in the derivation 
of the propensity score. Furthermore, the variable ‘partic-
ipating centre’ will always enter the propensity score 
model, in order to account for ‘undetectable’ differences 
between participating centres (eg, perioperative care 
protocols, institutional protocols, ethnicity and envi-
ronmental factors not collected in the Registry). Subse-
quent analyses with matched cohorts will be performed 
accounting for the matched nature of the data.
Further studies aimed at peculiar subgroup analyses are 
not considered at this moment, but the E-AVR Steering 
Committee will evaluate any study/substudy proposal 
from any researcher involved in the Registry, and accept/
reject it by vote after review and discussion about its 
feasibility. Therefore, research findings from the E–AVR 
registry will be disseminated among the scientific commu-
nity. They will be presented at international congresses 
and published in peer-reviewed international journals in 
the fields of cardiac surgery and cardiology. Any formal 
presentation or publication of data will be considered 
as a joint publication by the participating physician(s) 
and will follow the recommendations of the Interna-
tional Committee of Medical Journal Editors (ICMJE) 
for authorship. Data collection, analysis and writing 
process will be monitored by the Steering Committee of 
the E-AVR, which is made up of the PI and a local repre-
senting member from each of the participating centres. 
It is expected that periodical E-AVR Steering Committee 
meetings will occur, every 6 months for the first 2 years, 
yearly thereafter up to the end of follow-up. A complete 
list of the E-AVR Collaborators is reported in online 
supplementary appendix. The members of the Steering 
Committee will take responsibility for the quality of data 
through local audit.
Investigators will be eligible for authorship if they 
contribute substantially to study planning, data collec-
tion, data analysis and interpretation and writing and crit-
ical review of the manuscripts. Two authors per centre will 
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be included as main authors of each study. As a member 
of the Steering Committee, the local representing 
member will take any decisions on coauthorship related 
to his/her centre on the basis of the above criteria. Those 
researchers who plan a substudy, interpret the analysis 
and write the article will be the first and last authors of 
the study. Analyses will be performed and/or monitored 
by an independent Central Core Lab. When an article is 
submitted to a journal with a maximum number of coau-
thors, the Steering Committee will decide on the authors 
on the basis of their contribution to the design of the 
study, data collection, interpretation of data, writing and 
critical review of the paper.
In the event of future merging with other contempo-
rary registries (eg, collecting data on concurrent inter-
ventional—ie, percutaneous transfemoral, transcarotid 
or trans-axillary—TAVR procedures), the coauthorship 
of comparative studies (eg, between surgical and inter-
ventional treatments) will be defined by the Steering 
Committees of the different registries involved. However, 
data will not be made available for sharing until after 
publication of the principal results of the study. There-
after, anonymised individual patient data will be made 
available for secondary research, conditional on assur-
ance from the secondary researcher that the proposed 
used of the data is compliant with the MRC Policy on Data 
Preservation and Sharing regarding scientific quality, 
ethical requirements and value for money. Anonymised 
data will be shared as long as the patient has agreed and 
consented to this. A minimum requirement with respect 
to scientific quality will be a publicly available prespeci-
fied protocol describing the purpose, methods and anal-
ysis of the secondary research.
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